---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-077613"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:56:44.779338+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Korro Bio reports FY 2023 net loss of $81.2M; cash of $166.1M funds operations into 2026

## Summary
- Net loss of $81.2M in 2023 vs. $58.0M in 2022; R&D expenses $57.2M (up from $42.2M).
- Cash and short-term investments $166.1M as of Dec 31, 2023, compared to $55.2M at end of 2022.
- Regulatory filing for KRRO-110 in Alpha-1 Antitrypsin Deficiency on track for H2 2024.
- Preclinical data showed >50% editing using GalNAc conjugates with subcutaneous administration in mice.
- Cash runway into 2026; interim clinical readout for KRRO-110 expected in H2 2025.

## SEC filing metadata
- accession: 0001193125-24-077613
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312524077613/0001193125-24-077613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312524077613/d812258d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-077613
- JSON: https://secwatch.observer/filing/0001193125-24-077613.json
- Plain text: https://secwatch.observer/filing/0001193125-24-077613.txt

## Key facts
- Earnings Releases
  Korro Bio, Inc. reported the year ended December 31, 2023 results: net income $81.2 million.
  - Period: the year ended December 31, 2023
  - Net income: $81.2 million
  - Result: reported results
  source text: Korro’s net loss was $81.2 million for the year ended December 31, 2023, as compared to $58.0 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312524077613/0001193125-24-077613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.